BioSig Technologies Files 8-K on Director/Officer Changes & Shareholder Votes
Ticker: STEX · Form: 8-K · Filed: Dec 31, 2024 · CIK: 1530766
| Field | Detail |
|---|---|
| Company | Biosig Technologies, Inc. (STEX) |
| Form Type | 8-K |
| Filed Date | Dec 31, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, shareholder-vote
TL;DR
BioSig 8-K: Director changes, officer appointments, and shareholder votes filed Dec 31.
AI Summary
BioSig Technologies, Inc. filed an 8-K on December 31, 2024, reporting on several key events including the departure of directors or officers, the election of new directors, the appointment of certain officers, and compensatory arrangements. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
This filing provides crucial updates on the company's leadership and governance, which can impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with shareholder votes, can indicate internal shifts or strategic realignments that may carry inherent risks.
Key Players & Entities
- BioSig Technologies, Inc. (company) — Registrant
- December 31, 2024 (date) — Date of earliest event reported
FAQ
What specific items were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in this excerpt.
Who are the departing directors or officers?
The filing states that there was a departure of directors or certain officers, but their names are not specified in this excerpt.
Who were elected as new directors?
The filing mentions the election of directors, but the names of the newly elected directors are not provided in this excerpt.
What are the details of the compensatory arrangements for certain officers?
The filing notes that there are compensatory arrangements for certain officers, but the specifics of these arrangements are not detailed in this excerpt.
What is the principal executive office address for BioSig Technologies, Inc.?
The principal executive offices are located at 12424 Wilshire Blvd, Ste 745, Los Angeles, California, 90025.
Filing Stats: 1,084 words · 4 min read · ~4 pages · Grade level 13.6 · Accepted 2024-12-31 16:48:48
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BSGM N/A Indicate by ch
Filing Documents
- form8-k.htm (8-K) — 63KB
- ex10-1.htm (EX-10.1) — 11KB
- 0001493152-24-052735.txt ( ) — 250KB
- bsgm-20241231.xsd (EX-101.SCH) — 3KB
- bsgm-20241231_lab.xml (EX-101.LAB) — 33KB
- bsgm-20241231_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSIG TECHNOLOGIES, INC. Date: December 31, 2024 By: /s/ Anthony Amato Name: Anthony Amato Title: Chief Executive Officer